9 Meters Biopharma, Inc. NMTR
Set alert
0.07 +0.07 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.04M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.27
- Beta
- 1.48
- Short ratio
- 7.78
- Inst. own
- 16.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 21, 2023
- 50-d avg
- 0.7188
- 200-d avg
- 1.73
- 1y target
- 10.38
1Y chart
Events in this range
- Aug 15, 2022Earnings: —; estimate -0.8; surprise —%
- Sep 27, 2022Rating: Oppenheimer · — → Outperform
- Oct 18, 2022Split: 1 for 20
- Nov 8, 2022Earnings: —; estimate -0.83; surprise —%
- Nov 10, 2022Rating: BMO Capital · — → Outperform
- Feb 13, 2023Rating: Citigroup · — → Neutral
- Mar 20, 2023Downgrade: Truist Securities · Buy → Hold
- Mar 28, 2023Earnings: —; estimate -0.8; surprise —%
- May 15, 2023Earnings: —; estimate -0.79; surprise —%
- May 18, 2023Rating: Citigroup · Neutral → Neutral
- Jun 1, 2023Rating: Citigroup · Neutral → Neutral
Signals (31)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jul 18, 2023 | 3 years ago |
| RSI: Oversold | Jul 18, 2023 | 3 years ago |
| MACD: Buy Signal | May 12, 2023 | 3 years ago |
| RSI: Oversold | May 11, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 24, 2023 | 3 years ago |
| RSI: Oversold | Apr 24, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 27, 2023 | 3 years ago |
| RSI: Oversold | Mar 10, 2023 | 3 years ago |
| SMA: Bearish | Feb 22, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 13, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 6, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 27, 2023 | 3 years ago |
| RSI: Overbought | Jan 5, 2023 | 3 years ago |
| SMA: Bullish | Jan 4, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 23, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 16, 2022 | 3 years ago |
| RSI: Oversold | Dec 12, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 3, 2022 | 4 years ago |
| RSI: Oversold | Nov 2, 2022 | 4 years ago |
| RSI: Oversold | Oct 18, 2022 | 4 years ago |
Newest 20 of 31.
Analyst view
Consensus: buy
Buy
Price target (mean) 10.38 +14276.7% upside
Now 0.0722
- Target (low)
- 0.75
- Target (mean)
- 10.38
- Target (high)
- 20.00
Recommendation trend
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.57 | -1.06 – -0.41 | -0.80 | +28.8% | 0 | 0.0% | 5 |
| Next quarter | -0.40 | -1.06 – 0.34 | -0.72 | +44.4% | 0 | 0.0% | 5 |
| Current year | -2.18 | -4.20 – -1.07 | -3.38 | +35.5% | 2.50M | 0.0% | 5 |
| Next year | -2.53 | -4.50 – -1.23 | -2.18 | -16.1% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Citigroup | Maintained | Neutral | Neutral |
| May 18, 2023 | Citigroup | Maintained | Neutral | Neutral |
| Mar 20, 2023 | Truist Securities | Downgrade | Buy | Hold |
| Feb 13, 2023 | Citigroup | Initiated | — | Neutral |
| Nov 10, 2022 | BMO Capital | Maintained | — | Outperform |
| Sep 27, 2022 | Oppenheimer | Maintained | — | Outperform |
| Jul 1, 2022 | Maxim Group | Downgrade | Buy | Hold |
| Jun 22, 2022 | Truist Securities | Maintained | — | Buy |
| Jun 22, 2022 | BMO Capital | Maintained | — | Outperform |
| Jul 8, 2021 | BMO Capital | Initiated | — | Outperform |
| Jun 4, 2021 | Citigroup | Initiated | — | Buy |
| Jan 29, 2021 | Oppenheimer | Initiated | — | Outperform |
| Sep 23, 2020 | William Blair | Initiated | — | Outperform |
| Aug 18, 2020 | Brookline Capital | Initiated | — | Buy |